New hope for kids with kidney disease: rituximab cuts relapse risk
NCT ID NCT07049172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether rituximab, a medication that targets certain immune cells, could help children with a challenging form of nephrotic syndrome (a kidney disease) that keeps coming back. 91 children were split into two groups: one received rituximab plus special nursing care, the other received a standard drug (tacrolimus) plus the same care. The goal was to see which approach better prevented relapses and improved quality of life over 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wuhan Children's Hospital
Wuhan, Hubei, 430015, China